title: First intention IVF protocol for polycystic ovaries: does oral contraceptive pill pretreatment influence COH outcome?
abstract: BACKGROUND
  Morphological aspect of polycystic ovaries (PCO) is a very common finding in an IVF center population: this includes PCOS patients identified in 18-25% of the couples presenting with infertility and so called "sonographic PCO only" the prevalence of which has been estimated as high as 33% in asymptomatic patients. Finding the optimal first intention IVF protocol for polycystic ovaries patients is still challenging in order to improve the controlled ovarian hyperstimulation (COH) outcome while avoiding ovarian hyperstimulation syndrome (OHSS). It has been suggested that women with PCO would benefit from a longer period of pituitary down-regulation. The purpose of this study was to compare an extended duration of OCP pretreatment with a classic GnRH agonist protocol.
  
  
  METHODS
  A single center prospective non-randomized study was performed from January 2009 to December 2010 in the Lille University Hospital including 113 women diagnosed with PCO(S) according to the Rotterdam ultrasonographic criteria and undergoing their first IVF attempt. Comprehensive hormonal and ultra-sonographic assessments were collected during COH in these patients. LH and androgen suppression and dynamics of follicular growth were compared between the two protocols as well as the COH outcome in terms of oocyte/embryo number and quality, implantation and pregnancy rates.
  
  
  RESULTS
  No significant difference was observed between the two groups concerning dynamics of follicular growth and hormonal values. Clinical and ongoing pregnancy rates were significantly lower in the OCP group despite same oocyte and embryo quality. Nevertheless, the cumulative pregnancy rate did not differ between the two groups. The incidence of OHSS was not statistically significant.
  
  
  CONCLUSIONS
  Extended duration of OCP pretreatment, as a first intention IVF protocol for PCO patients, does not improve the pattern of follicular growth nor the oocyte and embryo quality.
authors.affiliation: IVF center of Jeanne de Flandre Hospital, Department of Endocrine Gynaecology and Reproductive Medicine, Centre Hospitalier Régional et Universitaire CHRU, Rue Eugène Avinée, 59037, Lille Cedex, France. christine.decanter@chru-lille.fr
authors.forename: Christine
authors.initials: C
authors.lastname: Decanter
authors.forename: Geoffroy
authors.initials: G
authors.lastname: Robin
authors.forename: Patricia
authors.initials: P
authors.lastname: Thomas
authors.forename: Maryse
authors.initials: M
authors.lastname: Leroy
authors.forename: Catherine
authors.initials: C
authors.lastname: Lefebvre
authors.forename: Benoit
authors.initials: B
authors.lastname: Soudan
authors.forename: Valerie
authors.initials: V
authors.lastname: Lefebvre-Khalil
authors.forename: Brigitte
authors.initials: B
authors.lastname: Leroy-Martin
authors.forename: Didier
authors.initials: D
authors.lastname: Dewailly
mesh_terms: D000328:Adult; D000735:Androstenedione / Q000097:blood; D003276:Contraceptives, Oral / Q000627:therapeutic use*; D017135:Desogestrel / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004624:Embryo Transfer; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use; D014463:Ultrasonography; D055815:Young Adult
chemical_list: D003276:Contraceptives, Oral; D011994:Recombinant Proteins; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D000735:Androstenedione; D004997:Ethinyl Estradiol; D017135:Desogestrel; D005640:Follicle Stimulating Hormone